## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.6% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($24.61)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. ACADIA Pharmaceuticals (NASDAQ:ACAD) Cut to "Hold" at Wall Street Zen**
- Source: MarketBeat | 20260103T170921 | Neutral | Relevance: 100%
- Wall Street Zen has downgraded ACADIA Pharmaceuticals (NASDAQ:ACAD) from "buy" to "hold." This decision follows ACADIA's strong financial performance, beating EPS and revenue estimates, and maintaining a healthy net margin. Despite the downgrade, the consensus analyst rating for ACADIA Pharmaceuticals, which focuses on CNS disorders, remains a "Moderate Buy" with an average target price of $30.47.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | HC Wainwright & | $37 | $32 | +16% |
| 2025-12-11 | Stifel | $25 | $24 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | HC Wainwright & | main | Buy |
| 2025-12-11 | Stifel | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (8.0%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Analyst sentiment positive (2 raises, avg +10%, $30 target (+17%)). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.4B |
| Beta | 0.68 |
| 52W Range | $13.40 - $28.35 |
| Short Interest | 8.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 32.1 |
| Current P/E | 32.0 |
| YoY Growth | -0.5% |
| EPS Direction | RISING |

### Technicals

MRS_10 deteriorating from -1.1% to -3.6% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.6pp (needs >3.0% for momentum thesis). Underperforming sector by 4.2pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). RSI neutral at 48. OFD pattern: -DBN (Indecision).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.60% (CS: 6) | Weak |
| RSI_14 | 48.3 | Neutral |
| MACD Histogram | -0.28 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 1.050x | Above |
| vs SMA200 | 1.193x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $26.15
- **Stop Loss:** $24.61 (5.9% risk)
- **Target:** $27.69 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 560
- **Position Value:** $14,644.00
- **Portfolio %:** 14.64%
- **Risk Dollars:** $862.50
- **Risk Per Trade:** 0.86%
- **Modifiers:** L1 115% | L2 75% | Combined 0.86x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

*NORMAL regime with moderate risk appetite. VIX remains calm at 14.9 (8th percentile) with positive yield curve (+65bps) and healthy breadth (59.2%), though elevated put/call ratio (1.27) suggests institutional hedging despite surface calm. Focus on quality with awareness of hedging activity divergence.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-07 09:35 | MRS_10*